Integrating Novel Approaches to HER2-Mutated NSCLC Management

On August 7, 2025, a select group of hematologist-oncologists and medical oncologists from academic and cancer specialty institutions participated in a virtual workshop moderated by Joshua Sabari, MD, where they discussed insights and considerations for identifying and managing HER2-mutated non–small cell lung cancer, and provided perspectives on recently presented data from trials evaluating antibody-drug conjugates and TKIs for this patient population.